The purpose of this work was to develop
Cremophor(®) EL-free nanoparticles (NPs) loaded with
Paclitaxel (PTX) in order to improve the drug i.v. pharmacokinetic profile and to evaluate its activity against commercially available formulations such as
Taxol(®) and
Abraxane(®). PTX-loaded poly(ε-
caprolactone)-
alpha tocopheryl polyethylene glycol 1000 succinate (PCL-
TPGS) NPs were prepared using three different techniques: (i) by nanoprecipitation (NPr-method), (ii) by
emulsion-
solvent evaporation homogenized with an Ultra-Turrax(®) (UT-method) and (iii) by
emulsion-
solvent evaporation homogenized with an ultrasonicator (US-method). The NPs prepared by US-method showed the smallest size and the highest drug content. The NPs exhibited a slow and continuous release of PTX. The in vitro anti-tumoral activity was assessed using two human
breast cancer cell lines (MCF-7 and MDA-MB-231) with the WTS assay. Cytotoxicity studies with both cell lines showed that PTX-loaded PCL-
TPGS NPs exhibited better anti-
cancer activity compared to PTX
solution and the commercial formulation
Abraxane(®) at different concentrations. Importantly, in the case of triple negative MDA-MB-231
breast cancer cells, the IC50 value for PTX-loaded PCL-
TPGS NPs was 7.8 times lower than
Abraxane(®). Finally, in vivo studies demonstrated that PTX-loaded PCL-
TPGS NPs exhibited longer systemic circulation time and slower plasma elimination rate than
Taxol(®) and
Abraxane(®). Therefore, the novel NPs investigated might be an alternative nanotechnological platform for PTX delivery system in
cancer chemotherapy.